Q-omics provides the consensus-scored ATP8B3 profile across patient tissues and cancer cell-line models. ATP8B3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ATP8B3 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ATP8B3 RNA expression shows 19,768 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where ATP8B3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ATP8B3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ATP8B3 survival associations across molecular data types. ATP8B3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (12) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ATP8B3 RNA expression–survival associations across cancer types. High ATP8B3 expression shows unfavorable associations in UVM, KIRC, KICH, MESO and LUAD, but favorable associations in UCEC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ATP8B3 RNA expression.
This table summarizes ATP8B3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ATP8B3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ATP8B3 shows higher tumor expression in KIRC, HNSC, KIRP, LUAD, LIHC and BRCA. The KIRC box plot shows higher ATP8B3 RNA expression in tumor versus normal tissue (log2 FC = +2.140, t-test p < 0.001).
This table shows molecular features associated with ATP8B3 in patient tissues and cancer cell lines. In patient samples, ATP8B3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ATP8B3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
